Syeda Masooma Jafri

Syeda Masooma Jafri

Auto-generated profile, based on publicly available information

Syeda Masooma Jafri

Dow University of Health Sciences, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2026 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SJSyeda Masooma Jafri
Syeda Masooma Jafri
MSMuhammad Shahzou Shah
Muhammad Shahzou Shah
JNJaveria Nawaz
Javeria Nawaz
ZSZainab Ali Siddiqui
Zainab Ali Siddiqui
MFMinhal Faisal
Minhal Faisal
RJRana Taha Jamal
Rana Taha Jamal

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
ABAsia Batool
Asia Batool
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
SKSaifullah Khan
Saifullah Khan
AAAlisha Ahmad
Alisha Ahmad
AAAiza Ahsan
Aiza Ahsan
EJEvardo Barros de Deus Nunes Junior
Evardo Barros de Deus Nunes Junior
Background: Atopic dermatitis is a chronic inflammatory skin condition characterized by eczematous lesions and pruritus, which can significantly impair quality of life. Biologics have been introduced for the treatment; however, due to safety concerns, investigations for these systemic drugs continue. Lebrikizumab, a monoclonal antibody inhibiting IL‐13, not only reduces the immunological response but also minimizes the destructive effects of these cytokines on skin barriers. This meta‐analysis was conducted to assess the efficacy and safety profile of lebrikizumab in patients with atopic dermatitis. Methods: A systematic review and meta‐analysis were conducted in accordance with the PRISMA guidelines. From conception until October 2025, literature was searched on PubMed, Embase, the Cochrane Library, and Scopus. Data were pooled from 4 studies comprising 1037 patients. Outcomes assessed include achievement of IGA (0.1) and ≥ 2‐point score from baseline to 16 weeks, EASI‐75 and EASI‐90 at 16 weeks, DLQI 4‐point improvement, DLQI, and reduction in sleep loss score and adverse events. Standardized mean differences (SMDs) or odds ratios (ORs) were calculated with 95% confidence intervals (CIs), and heterogeneity was examined using the I 2 statistic. Results: Lebrikizumab was significantly superior to placebo in achieving IGA (0.1) (OR = 2.88; 95% CI: 1.73 to 4.79; p < 0.001) and EASI‐75 (OR = 2.98; 95% CI: 1.76 to 5.05; p < 0.001) at Week 16. It was also associated with DLQI 4‐point improvement (OR = 3.99; 95% CI: 1.51 to 10.56; p = 0.005), pruritus NRS ≥ 4‐point improvement (OR = 2.80; 95% CI: 1.56 to 5.04; p = 0.006), and DLQI (MD = −2.13; 95% CI: −3.55 to −0.71) from baseline to 16 weeks. Higher rates of treatment‐emergent adverse events (TEAEs) (OD = 1.42; 95% CI: 1.07 to 1.89; p = 0.02) and moderate AEs (OD = 1.53; 95% CI: 1.04 to 2.25; p = 0.03) were associated with lebrikizumab. The risk of serious adverse effects and infections was comparable across the two groups. Conclusion: Lebrikizumab shows significant benefit in improving atopic dermatitis treatment by IGA (0.1), and ≥ 2‐point reduction, higher EASI‐75 response, and reduction in DLQI and pruritus score. However, lebrikizumab is associated with a higher risk of TEAS and moderate AEs.

23 June 2026 in Lasers in Medical Science
Verified
Journal Article
Open access
PDF file
ABAsia Batool
Asia Batool
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
FMFakhar e Mahin
Fakhar e Mahin
JNJaveria Nawaz
Javeria Nawaz
SJSyeda Masooma Jafri
Syeda Masooma Jafri
HAHasibullah Aminpoor
Hasibullah Aminpoor
Facial acne scarring is a widely prevalent dermatological disease manifested as a permanent aftereffect of acne vulgaris. While fractional CO₂ laser and needling procedures are essential to treating atrophic acne scars, comparative and safety data remains limited. This systematic review and meta-analysis directly compares their efficacy and safety. According to PRISMA guidelines, PubMed, Cochrane, Google Scholar, and ClinicalTrials.gov were systematically searched. Only studies comparing fractional CO₂ laser with needling-based monotherapy treating facial atrophic acne scars in adults were included. A random-effects model was employed for meta-analysis using Review Manager (RevMan) to compare efficacy and safety outcomes. A total of 17 studies were included in the meta-analysis. For primary efficacy outcomes, the results were non-significant for mean scar score reduction (SMD: -1.08, 95% CI: [-2.48, 0.32], I² = 97%) or mean quantitative scar reduction (SMD: 0.12, 95% CI: [-0.80, 1.04], I² = 92%), with significant heterogeneity. However, categorical treatment success was significantly high for CO₂ laser (RR: 1.10, 95% CI: [1.01, 1.20], I² = 0%). For safety outcomes, fractional CO₂ laser showed significantly high risk of post-inflammatory hyperpigmentation (PIH) as compared to standard microneedling (RR: 3.04, 95% CI: [1.49, 6.21], I² = 3%), but showed significantly low pain scores as compared to RF microneedling (SMD: -0.74, 95% CI: [-1.27, -0.21], I² = 0%). No significant differences were found for erythema, crusting/scabbing, or edema. Both fractional CO₂ laser and microneedling procedures show comparable efficacy in treating atrophic acne scars, however, patient variables such as skin type, scar type, and possible complications should be taken into consideration. Moreover, further tailored therapies are crucial to treating acne scars with low risk for complications.

7 May 2026 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
RSRida Shakeel
Rida Shakeel
TBTuba Basit
Tuba Basit
SCSohaib Aftab Ahmad Chaudhry
Sohaib Aftab Ahmad Chaudhry
HNHuzaifa Sabir Nawaz
Huzaifa Sabir Nawaz
ATAmal Tahir
Amal Tahir
MFMuhammad Aqib Faizan
Muhammad Aqib Faizan
Background: Secondary mitral regurgitation (SMR) worsens outcomes in advanced heart failure. Transcatheter edge-to-edge repair (TEER) and left ventricular assist device (LVAD) implantation represent advanced treatment options for patients with persistent symptoms despite guideline-directed medical therapy (GDMT). Methods: A scoping review using a PICO framework identified contemporary studies published up to 2025 involving adults with advanced heart failure (NYHA III–IV, INTERMACS 1–7) and ≥moderate SMR. Outcomes included mortality, heart failure hospitalizations, functional status, mitral regurgitation reduction, ventricular remodeling, complications, and quality of life. Results: Nine studies including over 2,000 patients were analyzed (mean age 60–72 years; LVEF 15–33%). TEER was associated with lower mortality and fewer heart failure hospitalizations compared with GDMT in selected patients. LVAD recipients generally had more advanced disease (predominantly INTERMACS 1–3) with higher early mortality but substantial functional improvement. TEER achieved MR ≤ 2 + in 84–99% of patients with low procedural complication rates (1–9%), whereas LVAD therapy demonstrated greater functional improvement but higher device-related complications. Conclusion: TEER is associated with improved outcomes in selected patients with advanced heart failure and SMR, while LVAD therapy remains essential for patients with end-stage disease requiring durable circulatory support.

16 September 2026 in Cardio-Oncology
Verified
Journal Article
Open access
PDF file
KMKainat Mehmood
Kainat Mehmood
SJSyeda Masooma Jafri
Syeda Masooma Jafri
BHBareeha Haider
Bareeha Haider
SJShah Jahan
Shah Jahan
AAAiza Ahsan
Aiza Ahsan
AMAbubakr Mahmoud
Abubakr Mahmoud
Chemotherapy-induced cardiotoxicity, particularly from anthracyclines, limits treatment in oncology patients. Carvedilol, a third-generation β-blocker

15 June 2026 in Clinical Cardiology
Verified
Journal Article
Open access
ESEmad Uddin Sajid
Emad Uddin Sajid
MAMuhammad Hasnain Azeem
Muhammad Hasnain Azeem
AFAlishba Fatima
Alishba Fatima
SJSyeda Masooma Jafri
Syeda Masooma Jafri
DHDanish Hassan
Danish Hassan
DBDanish Bawa
Danish Bawa
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.